Savara Secures European Patent Protection for MOLBREEVI Through 2041, Strengthening IP Portfolio for Rare Lung Disease Therapy
核心洞察
The European Patent Office (搜索) intends to grant Savara a patent for MOLBREEVI (搜索)'s liquid formulation, providing protection until March 2041 for this investigational autoimmune PAP (搜索) therapy.
Savara was also recently granted a European patent covering the drug-device combination of MOLBREEVI (搜索) with PARI's eFlow nebulizer system, extending protection through March 2043.
The company expects to resubmit its BLA to the FDA this month and plans to submit MAA applications in the EU and UK by the end of Q1 2026.
Savara Inc. announced that the European Patent Office (搜索) (EPO) has notified the company of its intention to grant a patent application covering the liquid formulation of MOLBREEVI (搜索), an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (搜索) (GM-CSF) for treating autoimmune pulmonary alveolar proteinosis (搜索) (PAP). Once granted, this patent will provide protection for MOLBREEVI in Europe until March 2041.
The announcement follows Savara's recent receipt of European Patent No. 4 496 611, jointly held with PARI Pharma GmbH, which covers the drug-device combination of MOLBREEVI (搜索) delivered via PARI's proprietary eFlow nebulizer system. This patent extends protection through March 2043.
"The liquid formulation and drug-device patents will provide protection in Europe through March 2041 and March 2043, respectively, and strengthen the Company's intellectual property portfolio for MOLBREEVI (搜索), our potentially first-in-class therapy to treat autoimmune PAP (搜索)," said Matt Pauls, Chair and Chief Executive Officer of Savara.
Regulatory Timeline and Designations
Savara expects to resubmit the MOLBREEVI (搜索) Biologics License Application (BLA) to the FDA this month and is preparing to submit Marketing Authorization Application (MAA) submissions in the EU and the UK by the end of the first quarter of 2026. Upon approval in the EU, MOLBREEVI will have 10 years of Orphan Drug regulatory exclusivity.
MOLBREEVI (搜索) has received multiple regulatory designations recognizing its potential therapeutic value. The U.S. Food and Drug Administration has granted the therapy Fast Track and Breakthrough Therapy Designations, while both the FDA and European Medicines Agency (搜索) have provided Orphan Drug Designation. The UK's Medicines and Healthcare Products Regulatory Agency has awarded Innovation Passport and Promising Innovative Medicine designations.
Understanding Autoimmune PAP
Autoimmune PAP (搜索) is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Surfactant, consisting of proteins and lipids, is an important physiological substance that lines the alveoli to prevent them from collapsing. In healthy lungs, excess surfactant is cleared and digested by immune cells called alveolar macrophages.
Alveolar macrophages require stimulation by granulocyte-macrophage colony-stimulating factor (搜索) (GM-CSF) to function properly in clearing surfactant. However, in autoimmune PAP (搜索), GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. This results in excess surfactant accumulation in the alveoli, causing impaired gas exchange and clinical symptoms including shortness of breath, cough, and frequent fatigue.
Patients may also experience episodes of fever, chest pain, or coughing up blood, particularly if secondary lung infection develops. Long-term complications can include lung fibrosis (搜索) and the potential need for lung transplantation.
Drug-Device Innovation
The proprietary eFlow nebulizer system has been specifically optimized for MOLBREEVI (搜索) delivery. Following approval, this system is planned to be commercially marketed under the name Vespera Nebulizer System. The drug-device combination represents a tailored approach to aerosol delivery for this specific therapeutic application.
PARI Pharma GmbH, a global leader in aerosol delivery device development, specializes in pharmaceutical licensing partnerships and offers customizable eFlow Technology mesh nebulizers. Drug-specific eFlow nebulizers are currently part of numerous clinical studies and are commercially available in several countries.
Development Status
MOLBREEVI (搜索), with the generic name molgramostim inhalation solution, is currently in Phase 3 development. The therapy represents Savara's lead program as the clinical-stage biopharmaceutical company focuses on rare respiratory diseases. The company's management team brings significant experience in rare respiratory diseases and pulmonary medicine, with expertise in identifying unmet needs and advancing product candidates toward approval and commercialization.